Janus Henderson Capital Funds Plc - Global Life Sciences Fund on Praxis Precision Medicines, Inc.
Thesis
Praxis contributed positively after favourable regulatory updates on two key pipeline programs. FDA mid-cycle reviews identified no major safety or efficacy concerns for ulixacaltamide in essential tremor or relutrigine in rare genetic epilepsies, and neither application required an advisory committee review. Praxis is also preparing rapidly for commercial launches, signalling confidence in the programs as they move closer to potential approval.
“The company is also rapidly making commercial preparations for launch, underscoring its conviction in these pipeline programs.”